Akashi Therapeutics

A year after patient death, Akashi gets FDA OK to resume DMD trial

Akashi Therapeutics has been given the FDA go-ahead to restart tests for its Duchenne muscular dystrophy candidate HT-100 (delayed-release halofuginone), just over a year after the test was suspended after a death.

Ben Adams Mar 22, 2017 8:19am